Patient quality of life in adult ALL
Zack Pemberton-Whiteley (UK)
23 Jan 2020
CAR-T cell therapy for ALL: Current challenges and future approaches
Dr Sara Ghorashian - University College London, London, UK
23 Jan 2020
Considerations for treatment sequencing in B-ALL
Prof Nicola Gökbuget - Universitätsklinikum Frankfurt, Frankfurt, Germany
23 Jan 2020
CART-T cell therapy in young patients with relapsed/refractory ALL
Prof Peter Bader - Universitätsklinikum Frankfurt, Frankfurt, Germany
23 Jan 2020
HSCT: Donor selection for patients with ALL
Prof Sebastian Giebel - The Maria Skłodowska-Curie Institute of Oncology, Gliwic...
23 Jan 2020
Therapy of Ph-positive adult ALL
Prof Oliver Ottmann - Cardiff University, Cardiff, UK
23 Jan 2020
The role of blinatumomab followed by HSCT in paediatric patients with ALL
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
23 Jan 2020
Defining the role of immunotherapy in B-cell ALL
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
23 Jan 2020
Long-term toxicities in paediatric ALL
Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark
23 Jan 2020
How is minimal residual disease managed in patients with ALL?
Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy
23 Jan 2020
BLAST: Blinatumomab for minimal residual disease in patients with ALL
Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy
23 Jan 2020
Frontline therapy of ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
23 Jan 2020
